Ascendis Pharma AS (A71) - Total Liabilities

Latest as of March 2026: €1.52 Billion EUR ≈ $1.77 Billion USD

Based on the latest financial reports, Ascendis Pharma AS (A71) has total liabilities worth €1.52 Billion EUR (≈ $1.77 Billion USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore Ascendis Pharma AS (A71) equity growth momentum to track the company's year-over-year net asset growth rate.

Ascendis Pharma AS - Total Liabilities Trend (2016–2025)

This chart illustrates how Ascendis Pharma AS's total liabilities have evolved over time, based on quarterly financial data. See cash generation quality of Ascendis Pharma AS to measure how efficiently the company converts operating cash flow to free cash.

Ascendis Pharma AS Competitors by Total Liabilities

The table below lists competitors of Ascendis Pharma AS ranked by their total liabilities.

Company	Country	Total Liabilities
Zhen Ding Technology Holding Ltd TW:4958	Taiwan	NT$109.33 Billion
Equity Lifestyle Properties Inc NYSE:ELS	USA	$3.93 Billion
Permian Resources Corporation NYSE:PR	USA	$6.05 Billion
Gaming & Leisure Properties NASDAQ:GLPI	USA	$7.83 Billion
SGH Ltd AU:SGH	Australia	AU$7.81 Billion
TransUnion NYSE:TRU	USA	$7.13 Billion
Ally Financial Inc NYSE:ALLY	USA	$180.50 Billion
AltaGas Ltd TO:ALA	Canada	CA$17.50 Billion

Liability Composition Analysis (2016–2025)

This chart breaks down Ascendis Pharma AS's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Ascendis Pharma AS (A71) total market value.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	1.00	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	3.11	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.76	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Ascendis Pharma AS's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Ascendis Pharma AS (2016–2025)

The table below shows the annual total liabilities of Ascendis Pharma AS from 2016 to 2025.

Year	Total Liabilities	Change
2025-12-31	€1.47 Billion ≈ $1.71 Billion	+14.02%
2024-12-31	€1.29 Billion ≈ $1.50 Billion	+32.32%
2023-12-31	€971.28 Million ≈ $1.14 Billion	+17.53%
2022-12-31	€826.39 Million ≈ $966.14 Million	+310.56%
2021-12-31	€201.29 Million ≈ $235.32 Million	+42.67%
2020-12-31	€141.08 Million ≈ $164.94 Million	+77.20%
2019-12-31	€79.62 Million ≈ $93.08 Million	+104.58%
2018-12-31	€38.92 Million ≈ $45.50 Million	+63.74%
2017-12-31	€23.77 Million ≈ $27.79 Million	+76.61%
2016-12-31	€13.46 Million ≈ $15.73 Million	--

About Ascendis Pharma AS

F:A71 Germany Biotechnology

Market Cap

$14.79 Billion

€12.65 Billion EUR

Market Cap Rank

#1845 Global

#391 in Germany

Share Price

€206.00

Change (1 day)

+0.98%

52-Week Range

€170.00 - €210.00

All Time High

€210.00